Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Setmelanotide (Imcivree) vs Teriparatide (Forteo)
An educational, source-based comparison of Setmelanotide (Imcivree) and Teriparatide (Forteo) — how each peptide works, what it's researched for, and what to know before going deeper.
MC4R agonist for rare genetic obesity disorders.
Cyclic 8-amino-acid melanocortin-4 receptor (MC4R) agonist that restores signaling in the leptin–melanocortin pathway, addressing hyperphagia and obesity in specific genetic deficiencies (POMC, PCSK1, LEPR, Bardet–Biedl syndrome).
- POMC/LEPR/PCSK1 deficiency obesity
- Bardet–Biedl syndrome
- • FDA-approved.
- • Hyperpigmentation, injection-site reactions common.
Recombinant PTH(1-34) for severe osteoporosis.
Recombinant fragment of parathyroid hormone (amino acids 1–34). Intermittent dosing stimulates osteoblast activity more than osteoclasts, producing net bone formation and increased bone mineral density.
- Postmenopausal osteoporosis
- Male osteoporosis
- Glucocorticoid-induced osteoporosis
- • FDA-approved.
- • Lifetime use limited to 2 years; transient hypercalcemia possible.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Setmelanotide (Imcivree) | Setmelanotide phase 3 trials | Lancet Diabetes & Endocrinology | 2020 | Significant weight loss and hunger reduction in genetic obesity syndromes. |
| Teriparatide (Forteo) | Fracture Prevention Trial | NEJM | 2001 | Reduced vertebral fractures by 65% in postmenopausal women. |
Side-effect & safety grid
- FDA-approved.
- Hyperpigmentation, injection-site reactions common.
- FDA-approved.
- Lifetime use limited to 2 years; transient hypercalcemia possible.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Setmelanotide (Imcivree) vs Teriparatide (Forteo) — Key differences
- Class: Setmelanotide (Imcivree) is classified as Melanocortin Agonist · Metabolic, while Teriparatide (Forteo) is Parathyroid Hormone · Anabolic Bone.
- Primary research focus: Setmelanotide (Imcivree) — pomc/lepr/pcsk1 deficiency obesity; Teriparatide (Forteo) — postmenopausal osteoporosis.
- Tag: FDA-Approved · Rare Disease vs FDA-Approved · Bone.